(-0.02%) 5 212.75 points
(-0.01%) 39 022 points
(-0.02%) 18 196 points
(-0.59%) $77.92
(0.36%) $2.22
(0.07%) $2 325.90
(0.26%) $27.62
(-0.12%) $987.20
(0.11%) $0.931
(0.33%) $10.93
(0.17%) $0.801
(-1.11%) $90.43
Live Chart Being Loaded With Signals
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide...
Stats | |
---|---|
Today's Volume | 2.00 |
Average Volume | 30.00 |
Market Cap | 1.29B |
Next earnings date | ( $0 ) 2024-05-24 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 111.11 |
ATR14 | $0 (0.00%) |
Cosmo Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cosmo Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $111.61M |
Gross Profit: | $66.22M (59.33 %) |
EPS: | $0.0965 |
FY | 2023 |
Revenue: | $111.61M |
Gross Profit: | $66.22M (59.33 %) |
EPS: | $0.0965 |
FY | 2022 |
Revenue: | $110.81M |
Gross Profit: | $62.55M (56.44 %) |
EPS: | $1.140 |
Financial Reports:
No articles found.
Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators